trial · primary record
Isatuximab SC-OBDS
Plasma Cell Myeloma Refractory
| Phase | Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 64 |
| Primary completion | 2027-07-15 |
| Primary endpoint | Overall response rate (ORR) |
| Registry ID | NCT06356571 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:31:48.150Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06356571
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.